Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.68 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10693120 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10687830 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10691842 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10694438 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10691896 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL3033071 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10687786 | 0.99 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10693436 | 0.97 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL9777248 | 0.91 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10637098 | 0.88 | CYSLTR2 (0.53) | CYSLTR2CYSLTR1LMNAMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3400971-B1 | ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2021-08-04 | — | — | EP | claimed |
| EP-3400969-B1 | IMPLANTED DEVICE | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2021-05-19 | — | — | EP | claimed |
| US-10946121-B2 | Absorbable iron-based alloy implantable medical device | BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) | 2021-03-16 | — | — | US | claimed |
| EP-3400970-B1 | ABSORBABLE IRON-BASED ALLOY MEDICAL DEVICE IMPLANT | LIFETECH SCIENT SHENZHEN CO (CN) | 2021-03-03 | — | — | EP | claimed |
| US-20200215237-A1 | ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE | BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) | 2020-07-09 | — | — | US | claimed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | claimed |
| CN-110582305-A | Vectors and compositions for the treatment of hemoglobinopathies | 蓝鸟生物公司 | 2019-12-17 | — | — | CN | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | claimed |
| WO-2006044391-A1 | A METHOD OF REDUCING DRUG-INDUCED ADVERSE SIDE EFFECTS IN A PATIENT | INTERCEPT PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6756399-B2 | INHIBITORS OF ENZYMES THAT METABOLIZE ARACHIDONIC ACID; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-06-29 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0108592-B1 | LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1987-09-30 | — | — | EP | claimed |
| US-4661505-A | 4-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY) ALKANOIC ACIDS, TETRAZOLES, AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-04-28 | — | — | US | claimed |
| EP-0108592-A1 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1984-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | CYSLTR2 17/4885CYSLTR1 15/4885LMNA 1097/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | CYSLTR2 3991/4885CYSLTR1 4303/4885LMNA 1356/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | CYSLTR2 17/4885CYSLTR1 15/4885LMNA 1097/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | CYSLTR2 3273/4885CYSLTR1 2929/4885LMNA 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.